IMR Press / EJGO / Volume 37 / Issue 5 / DOI: 10.12892/ejgo3186.2016

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research
Effect of exemestane on the invasive growth of endometrial carcinoma HHUA cells
Show Less
1 Department of Gynecology, Yuhuangding Hospital, Medical College of Qingdao University, Yantai, China
Eur. J. Gynaecol. Oncol. 2016, 37(5), 674–677;
Published: 10 October 2016

Objective: To investigate the effect of exemestane on HHUA human endometrial carcinoma cells. Materials and Methods: The HHUA human endometrial carcinoma cells were treated with various concentrations of exemestane, and its effects on cell growth and apoptosis were investigated in vitro. The cell apoptosis was analyzed by flow cytometry and RT-PCR was used to investigate the expression of CD44s. The invasion ability of HHUA human endometrial carcinoma cells which treated with exemestane were assessed using transwell chamber model. Results: At increasing doses of exemestane, a simultaneous increase in apoptotic subpopulations was detected when compared with group A (p < 0.05); the CD44s expression was found to be suppressed after the exemestane treatment. The decrease was a dose-dependent with exemestane treatment. Conclusion: 6×10-8mol/L exemestane is an optimal dose to inhibit the expression of CD44s mRNA and inhibit the invasive growth of the endometrial carcinoma HHUA cells.
Endometrial neoplasms
Back to top